“There has never been a better time moving into Alzheimer’s research.”
“There has never been a better time moving into Alzheimer’s research.”
Alzheimer’s disease (AD) biomarkers are measureable before changes occur that are noticeable by individuals.
Testing the cerebrospinal fluid for Amyloid-β and Tau is a recognized diagnostic tool.
One new case every 3.2 seconds
9.9 million new cases of dementia are observed each year worldwide one new case occurse very 3.2 seconds.
A steady decline in brain function.
A healthy brain has 100 billion neurons and 100 trillion synapses . AD causes a severe loss of connectivity and brain atrophy.
Cases will double every 20 years.
Worldwide, at least 50 million people are living with AD or forms of dementia. Numbers keep rising.
Follow our blog and learn more about Tecan‘s automated solution for AD testing.
Early diagnosis of Alzheimer‘s disease with the Amyloid β 42/ 40 CSF concentration ratio : Analytical and clinical validation of the two novel assays.
Efficiency of the ratio of cerebrospinal fluid Aβ42/ Aβ40 concentrations in detecting Alzheimer’s disease. A step forward?
Tecan offers CE-IVD ELISA solutions for the quantitative detection of Amyloid-β (1-40), Amyloid-β (1-42), pTau* and hTau* for the diagnosis of Alzheimer’s disease, as well as several other products for dementia like NF-light* or sAPP-β* (RUO) in cerebrospinal fluid (CSF).
* Distributed by Tecan IBL International. Available only for restricted territories. Please contact us to receive more information.
The combined use of assays, process script and the Freedom EVOlyzer has to be validated individually on site by each laboratory.
Simply fill out the form below to learn more about our solutions.